MedTrace Logo

The Relevance of the Blood-brain Barrier to Cognitive Dysfunction and Alzheimer's Disease

NCT04093882 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 101

Last updated 2021-11-11

No results posted yet for this study

Summary

This study attempts to replicate the findings published in Nature Medicine by Nation and colleagues (2019). By using a large observational cohort (DZNE - Longitudinal Cognitive Impairment and Dementia Study; DELCODE) consisting of cognitively healthy individuals, individuals with subjective cognitive decline, mild cognitive impairment, and dementia due to Alzheimer's disease, an association between the blood-brain barrier and cognitive dysfunction is investigated. The integrity of the blood-brain barrier is investigated by using a novel MRI protocol as well as a novel biomarker in the cerebrospinal fluid.

Conditions

  • Blood Brain Barrier
  • Alzheimer Disease
  • Cognitive Dysfunction
  • Dementia

Interventions

DIAGNOSTIC_TEST

Contrast agent enhanced MRI using Gadovist

By using the contrast agent Gadovist we aim to visualize the blood-brain barrier. Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid.

Sponsors & Collaborators

  • Prof. Dr. med. Jochen Fiebach (Senior Physician)

    collaborator UNKNOWN

  • Charite University, Berlin, Germany

    lead OTHER

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-12
Primary Completion
2021-09-30
Completion
2021-09-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04093882 on ClinicalTrials.gov